Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
7.91
-0.17 (-2.10%)
At close: Jul 22, 2026, 4:00 PM EDT
7.95
+0.04 (0.51%)
After-hours: Jul 22, 2026, 7:34 PM EDT

Novavax Revenue

Novavax had revenue of $139.51M in the quarter ending March 31, 2026, a decrease of -79.07%. This brings the company's revenue in the last twelve months to $596.34M, down -52.48% year-over-year. In the year 2025, Novavax had annual revenue of $1.12B with 64.69% growth.

Revenue (ttm)
$596.34M
Revenue Growth
-52.48%
P/S Ratio
2.18
Revenue / Employee
$796,179
Employees
749
Market Cap
1.30B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20251.12B441.32M64.69%
Dec 31, 2024682.16M-301.54M-30.65%
Dec 31, 2023983.71M-998.17M-50.36%
Dec 31, 20221.98B835.58M72.89%
Dec 31, 20211.15B670.69M141.02%
Dec 31, 2020475.60M456.94M2,448.48%
Dec 31, 201918.66M-15.63M-45.57%
Dec 31, 201834.29M3.11M9.98%
Dec 31, 201731.18M15.82M103.06%
Dec 31, 201615.35M-20.90M-57.65%
Dec 31, 201536.25M5.59M18.24%
Dec 31, 201430.66M9.74M46.59%
Dec 31, 201320.92M-1.16M-5.26%
Dec 31, 201222.08M7.39M50.30%
Dec 31, 201114.69M14.35M4,182.22%
Dec 31, 2010343.00K18.00K5.54%
Dec 31, 2009325.00K-739.00K-69.45%
Dec 31, 20081.06M-449.00K-29.68%
Dec 31, 20071.51M-225.00K-12.95%
Dec 31, 20061.74M-3.61M-67.47%
Dec 31, 20055.34M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Ardelyx427.68M
MannKind360.78M
Immatics43.00M
Aktis Oncology8.28M
Absci1.84M
Inhibrx Biosciences1.30M
Revenue Rankings